Skip to main content
Top
Published in: BMC Health Services Research 1/2018

Open Access 01-12-2018 | Research article

Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings

Authors: Zipporah Kamuren, Gabriel Kigen, Alfred Keter, Alice Maritim

Published in: BMC Health Services Research | Issue 1/2018

Login to get access

Abstract

Background

Warfarin is a drug with narrow therapeutic index used in the management of thromboembolic disorders. Several factors affect its plasma concentrations with a resultant risk of toxicity. We examined the database of patients on warfarin therapy in order to establish the factors that affect the stability of INR and correlated them to clinical outcomes in resource limited settings.

Methods

We analysed retrospective data of patients admitted to adult medical wards at Moi Teaching and Referral Hospital (MTRH) in 2015. Inclusion criteria were patients with thromboembolic and related disorders and on warfarin treatment. Derived data included demographics, indications for warfarin use, co-prescribed drugs, co-morbidities, INR measurements, duration of hospital stay and clinical outcomes. Descriptive statistics were used to summarize the data. Pearson’s correlation coefficient was used to assess relationships between duration of hospitalization and number of INR tests. Regression splines were used to capture INR trends during the follow up period. Data was analysed using R v. 3.3.1.

Results

A total of 310 patients had thromboembolic disorders, out of which 63 met the study criteria.
The median age was 48 years, while the mean number of INR measurements was once every four days. Majority of patients did not achieve stable INR values, with only two having consecutive INR values within therapeutic goal. Patients who died had high INR levels. The median duration of hospital stay was 9 days (IQR: 7.0, 16.5). There was a significant correlation between length of stay in hospital and the number of times that INR were measured (Corr = 0.667, p < 0.001). The two most common indications for warfarin were DVT (64.4%) and atrial fibrillation (24.7%). All the patients had one or more comorbid conditions except for 11 with DVT alone, with cardiovascular diseases and infections being the most frequent, and on concomitant medications, majority of which are known to interact with warfarin.

Conclusions

It was difficult to achieve stable INR under the prevailing conditions despite the frequent tests.
The potential factors that may have contributed to the fluctuations include drug-drug interactions, frequency of INR tests, comorbidities and the short duration of hospital stay.
Literature
1.
go back to reference Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.CrossRef Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.CrossRef
2.
go back to reference Arbring K, Uppugunduri S, Lindahl TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res. 2013;13:85.CrossRef Arbring K, Uppugunduri S, Lindahl TL. Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res. 2013;13:85.CrossRef
3.
go back to reference Arcelus JI, Caprini JA, Monreal M, Suarez C, Gonzalez-Fajardo J. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg. 2003;38(5):916–22.CrossRef Arcelus JI, Caprini JA, Monreal M, Suarez C, Gonzalez-Fajardo J. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg. 2003;38(5):916–22.CrossRef
4.
go back to reference Avila CW, Aliti GB, Feijo MK, Rabelo ER. Pharmacological adherence to oral anticoagulant and factors that influence the international normalized ratio stability. Revista latino-americana de enfermagem. 2011;19(1):18–25.CrossRef Avila CW, Aliti GB, Feijo MK, Rabelo ER. Pharmacological adherence to oral anticoagulant and factors that influence the international normalized ratio stability. Revista latino-americana de enfermagem. 2011;19(1):18–25.CrossRef
5.
go back to reference Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012;125(2):183–9.CrossRef Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012;125(2):183–9.CrossRef
6.
go back to reference Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492–7.PubMed Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492–7.PubMed
7.
go back to reference Bibas M, Biava G, Antinori A. HIV-associated venous thromboembolism. Mediterranean journal of hematology and infectious diseases. 2011;3(1):e2011030.CrossRef Bibas M, Biava G, Antinori A. HIV-associated venous thromboembolism. Mediterranean journal of hematology and infectious diseases. 2011;3(1):e2011030.CrossRef
8.
go back to reference Björholt I, Andersson S, Nilsson GH, Krakau I. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract. 2007;8:6–6.CrossRef Björholt I, Andersson S, Nilsson GH, Krakau I. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam Pract. 2007;8:6–6.CrossRef
10.
go back to reference Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interactions involving warfarin: practice tool and practical management tips. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 2011;144(1):21 25.e29.CrossRef Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interactions involving warfarin: practice tool and practical management tips. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 2011;144(1):21 25.e29.CrossRef
11.
go back to reference Clark TR, Burns S. Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone. Am J Health Syst Pharm. 2011;68(17):1603–5.CrossRef Clark TR, Burns S. Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone. Am J Health Syst Pharm. 2011;68(17):1603–5.CrossRef
12.
go back to reference Couris R, Tataronis G, McCloskey W, Oertel L, Dallal G, Dwyer J, et al. Dietary vitamin K variability affects international normalized ratio (INR) coagulation indices. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition. 2006;76(2):65–74.CrossRef Couris R, Tataronis G, McCloskey W, Oertel L, Dallal G, Dwyer J, et al. Dietary vitamin K variability affects international normalized ratio (INR) coagulation indices. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition. 2006;76(2):65–74.CrossRef
13.
go back to reference Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDs. 2008;22(10):771–8.CrossRef Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDs. 2008;22(10):771–8.CrossRef
15.
go back to reference Dumas S, Rouleau-Mailloux E, Bouchama N, Lahcene H, Talajic M, Tardif JC, et al. Pillbox use and INR stability in a prospective cohort of new warfarin users. Journal of managed care & specialty pharmacy. 2016;22(6):676–84.CrossRef Dumas S, Rouleau-Mailloux E, Bouchama N, Lahcene H, Talajic M, Tardif JC, et al. Pillbox use and INR stability in a prospective cohort of new warfarin users. Journal of managed care & specialty pharmacy. 2016;22(6):676–84.CrossRef
16.
go back to reference Dumo PA, Kielbasa LA. Successful anticoagulation and continuation of tramadol therapy in the setting of a tramadol-warfarin interaction. Pharmacotherapy. 2006;26(11):1654–7.CrossRef Dumo PA, Kielbasa LA. Successful anticoagulation and continuation of tramadol therapy in the setting of a tramadol-warfarin interaction. Pharmacotherapy. 2006;26(11):1654–7.CrossRef
17.
go back to reference Gavronski M, Hartikainen S, Zharkovsky A. Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. Pharm Pract. 2012;10(1):9–16.CrossRef Gavronski M, Hartikainen S, Zharkovsky A. Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more. Pharm Pract. 2012;10(1):9–16.CrossRef
18.
go back to reference Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evidence-based Complementary and Alternative Medicine : eCAM. 2014;2014:957362. Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evidence-based Complementary and Alternative Medicine : eCAM. 2014;2014:957362.
19.
go back to reference Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70(8):725–33.CrossRef Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70(8):725–33.CrossRef
20.
go back to reference Ha NB, Regal RE. Anticoagulation in patients with cirrhosis: caught between a rock-liver and a hard place. Ann Pharmacother. 2016;50(5):402–9.CrossRef Ha NB, Regal RE. Anticoagulation in patients with cirrhosis: caught between a rock-liver and a hard place. Ann Pharmacother. 2016;50(5):402–9.CrossRef
21.
go back to reference Harding R, Simms V, Penfold S, Downing J, Powell RA, Mwangi-Powell F, et al. Availability of essential drugs for managing HIV-related pain and symptoms within 120 PEPFAR-funded health facilities in East Africa: a cross-sectional survey with onsite verification. Palliat Med. 2014;28(4):293–301.CrossRef Harding R, Simms V, Penfold S, Downing J, Powell RA, Mwangi-Powell F, et al. Availability of essential drugs for managing HIV-related pain and symptoms within 120 PEPFAR-funded health facilities in East Africa: a cross-sectional survey with onsite verification. Palliat Med. 2014;28(4):293–301.CrossRef
22.
go back to reference Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59(3):635–46.PubMed Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59(3):635–46.PubMed
23.
go back to reference Howard-Thompson A, Luckey A. Graves' disease and treatment effects on warfarin anticoagulation, vol. 2014; 2014. p. 292468. Howard-Thompson A, Luckey A. Graves' disease and treatment effects on warfarin anticoagulation, vol. 2014; 2014. p. 292468.
25.
go back to reference IREC (2014). The Institutional Research and Ethics Committee (IREC) of Moi University College of Health Sciences (MUCHS) & Moi Teaching & Referral Hospital (MTRH) [Accessed on 20/10/2016]; Available from: https://irec.or.ke/ IREC (2014). The Institutional Research and Ethics Committee (IREC) of Moi University College of Health Sciences (MUCHS) & Moi Teaching & Referral Hospital (MTRH) [Accessed on 20/10/2016]; Available from: https://​irec.​or.​ke/​
26.
go back to reference Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med. 2003;70(4):361–71.CrossRef Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med. 2003;70(4):361–71.CrossRef
27.
go back to reference Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. In: BMJ (Clinical research ed.) 350: h246; 2015. Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. In: BMJ (Clinical research ed.) 350: h246; 2015.
28.
go back to reference Kahlon P, Nabi S, Arshad A, Jabbar A, Haythem A. Warfarin dosing and time required to reach therapeutic international normalized ratio in patients with hypercoagulable conditions. Turkish Journal of Hematology. 2016;33(4):299–303.CrossRef Kahlon P, Nabi S, Arshad A, Jabbar A, Haythem A. Warfarin dosing and time required to reach therapeutic international normalized ratio in patients with hypercoagulable conditions. Turkish Journal of Hematology. 2016;33(4):299–303.CrossRef
29.
go back to reference Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circulation Cardiovascular quality and outcomes. 2012;5(5):615–21.CrossRef Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circulation Cardiovascular quality and outcomes. 2012;5(5):615–21.CrossRef
30.
go back to reference Lane MA, Devine ST, McDonald JR. High-risk antimicrobial prescriptions among ambulatory patients on warfarin. J Clin Pharm Ther. 2012;37(2):157–60.CrossRef Lane MA, Devine ST, McDonald JR. High-risk antimicrobial prescriptions among ambulatory patients on warfarin. J Clin Pharm Ther. 2012;37(2):157–60.CrossRef
31.
go back to reference Leite PM, Martins MAP, Castilho RO. Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016;83:14–21.CrossRef Leite PM, Martins MAP, Castilho RO. Review on mechanisms and interactions in concomitant use of herbs and warfarin therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016;83:14–21.CrossRef
32.
go back to reference Leung NH, Chen A, Yadav P, Gallien J. The impact of inventory management on stock-outs of essential drugs in sub-Saharan Africa: secondary analysis of a field experiment in Zambia. PLoS One. 2016;11(5):e0156026.CrossRef Leung NH, Chen A, Yadav P, Gallien J. The impact of inventory management on stock-outs of essential drugs in sub-Saharan Africa: secondary analysis of a field experiment in Zambia. PLoS One. 2016;11(5):e0156026.CrossRef
33.
go back to reference Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):287s–310s.CrossRef Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):287s–310s.CrossRef
34.
go back to reference Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. Journal of the American Society of Nephrology : JASN. 2009;20(4):912–21.CrossRef Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. Journal of the American Society of Nephrology : JASN. 2009;20(4):912–21.CrossRef
35.
go back to reference Lindh JD, Andersson ML, Mannheimer B. Adherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish register study. PLoS One. 2014;9(5):e97388.CrossRef Lindh JD, Andersson ML, Mannheimer B. Adherence to guidelines for avoiding drug interactions associated with warfarin--a Nationwide Swedish register study. PLoS One. 2014;9(5):e97388.CrossRef
36.
go back to reference Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29(2):171–81.CrossRef Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29(2):171–81.CrossRef
38.
go back to reference Meurer LN, Jamieson B, Guthmann R. Clinical inquiries. What is the interval for monitoring warfarin therapy once therapeutic levels have been achieved? The Journal of family practice. 2005;54(2):171–2.PubMed Meurer LN, Jamieson B, Guthmann R. Clinical inquiries. What is the interval for monitoring warfarin therapy once therapeutic levels have been achieved? The Journal of family practice. 2005;54(2):171–2.PubMed
39.
go back to reference Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84(12):1079–94.CrossRef Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84(12):1079–94.CrossRef
41.
go back to reference Nannaka VB, Jani N, Niazi M, Lvovsky D. Acute warfarin toxicity as initial manifestation of metastatic liver disease. Case reports in critical care. 2016;2016:7389087.CrossRef Nannaka VB, Jani N, Niazi M, Lvovsky D. Acute warfarin toxicity as initial manifestation of metastatic liver disease. Case reports in critical care. 2016;2016:7389087.CrossRef
42.
go back to reference Narum S, Solhaug V, Myhr K, Johansen PW, Brørs O, Kringen MK. Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system. Br J Clin Pharmacol. 2011;71(2):254–62.CrossRef Narum S, Solhaug V, Myhr K, Johansen PW, Brørs O, Kringen MK. Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system. Br J Clin Pharmacol. 2011;71(2):254–62.CrossRef
43.
go back to reference Neidecker M, Patel AA, Nelson WW, Reardon G. Use of warfarin in long-term care: a systematic review. BMC Geriatr. 2012;12:14.CrossRef Neidecker M, Patel AA, Nelson WW, Reardon G. Use of warfarin in long-term care: a systematic review. BMC Geriatr. 2012;12:14.CrossRef
44.
go back to reference Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm. 2015;37(1):53–9.CrossRef Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm. 2015;37(1):53–9.CrossRef
45.
go back to reference Noble S. Management of venous thromboembolism in the palliative care setting. Int J Palliat Nurs. 2007;13(12):574–9.CrossRef Noble S. Management of venous thromboembolism in the palliative care setting. Int J Palliat Nurs. 2007;13(12):574–9.CrossRef
46.
go back to reference Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ : British Medical Journal. 2002;325(7372):1073–5.CrossRef Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ : British Medical Journal. 2002;325(7372):1073–5.CrossRef
47.
go back to reference Passman R. Time in therapeutic range in warfarin-treated patients: is very good good enough? Jama. 2016;316(8):872–3.CrossRef Passman R. Time in therapeutic range in warfarin-treated patients: is very good good enough? Jama. 2016;316(8):872–3.CrossRef
48.
go back to reference Pastakia SD, Crisp WI, Schellhase EM, Manji I, Ouma MN, Akwanalo C. Implementation of a pharmacist managed anticoagulation clinic in Eldoret, Kenya. Southern Med Review. 2010;3(2). Pastakia SD, Crisp WI, Schellhase EM, Manji I, Ouma MN, Akwanalo C. Implementation of a pharmacist managed anticoagulation clinic in Eldoret, Kenya. Southern Med Review. 2010;3(2).
49.
go back to reference Patel KK, Mehdirad AA, Lim MJ, Ferreira SW, Mikolajczak PC, Stolker JM. Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. J Hosp Med. 2014;9(6):400–6.CrossRef Patel KK, Mehdirad AA, Lim MJ, Ferreira SW, Mikolajczak PC, Stolker JM. Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. J Hosp Med. 2014;9(6):400–6.CrossRef
50.
go back to reference Poller L. International normalized ratios (INR): the first 20 years. Journal of thrombosis and haemostasis : JTH. 2004;2(6):849–60.CrossRef Poller L. International normalized ratios (INR): the first 20 years. Journal of thrombosis and haemostasis : JTH. 2004;2(6):849–60.CrossRef
51.
go back to reference R (2017). R: a language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria; R Core team (2017). [Accessed 21 Nov 2017]; available from: https://www.r-project.org/ R (2017). R: a language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria; R Core team (2017). [Accessed 21 Nov 2017]; available from: https://​www.​r-project.​org/​
52.
go back to reference Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circulation. Cardiovascular quality and outcomes. 2014;7(5):664–9.CrossRef Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circulation. Cardiovascular quality and outcomes. 2014;7(5):664–9.CrossRef
53.
go back to reference Reiffel JA. Time in the therapeutic range for patients taking warfarin in clinical trials: useful, but also misleading, misused, and Overinterpreted. Circulation. 2017;135(16):1475–7.CrossRef Reiffel JA. Time in the therapeutic range for patients taking warfarin in clinical trials: useful, but also misleading, misused, and Overinterpreted. Circulation. 2017;135(16):1475–7.CrossRef
54.
go back to reference Rikala M, Hauta-Aho M, Helin-Salmivaara A, Lassila R, Korhonen MJ, Huupponen R. Co-prescribing of potentially interacting drugs during warfarin therapy - a population-based register study. Basic & clinical pharmacology & toxicology. 2015;117(2):126–32.CrossRef Rikala M, Hauta-Aho M, Helin-Salmivaara A, Lassila R, Korhonen MJ, Huupponen R. Co-prescribing of potentially interacting drugs during warfarin therapy - a population-based register study. Basic & clinical pharmacology & toxicology. 2015;117(2):126–32.CrossRef
55.
go back to reference Riva N, Ageno W. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost. 2015;41(2):178–87.CrossRef Riva N, Ageno W. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost. 2015;41(2):178–87.CrossRef
56.
go back to reference Rouaud A, Hanon O, Boureau A-S, Chapelet GG, de Decker L. Comorbidities against quality control of VKA therapy in non-Valvular atrial fibrillation: a French National Cross-Sectional Study. PLoS One. 2015;10(3):e0119043.CrossRef Rouaud A, Hanon O, Boureau A-S, Chapelet GG, de Decker L. Comorbidities against quality control of VKA therapy in non-Valvular atrial fibrillation: a French National Cross-Sectional Study. PLoS One. 2015;10(3):e0119043.CrossRef
57.
go back to reference Sakaan SA, Hudson JQ, Oliphant CS, Tolley EA, Cummings C, Alabdan NA, et al. Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease. Pharmacotherapy. 2014;34(7):695–702.CrossRef Sakaan SA, Hudson JQ, Oliphant CS, Tolley EA, Cummings C, Alabdan NA, et al. Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease. Pharmacotherapy. 2014;34(7):695–702.CrossRef
58.
go back to reference Saum LM, Balmat RP. Ceftriaxone potentiates warfarin activity greater than other antibiotics in the treatment of urinary tract infections. J Pharm Pract. 2016;29(2):121–4.CrossRef Saum LM, Balmat RP. Ceftriaxone potentiates warfarin activity greater than other antibiotics in the treatment of urinary tract infections. J Pharm Pract. 2016;29(2):121–4.CrossRef
59.
go back to reference Seet RC, Rabinstein AA, Christianson TJ, Petty GW, Brown RD Jr. Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2013;22(4):561–9.CrossRef Seet RC, Rabinstein AA, Christianson TJ, Petty GW, Brown RD Jr. Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2013;22(4):561–9.CrossRef
60.
go back to reference Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(3):300–9.CrossRef Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(3):300–9.CrossRef
61.
go back to reference Singh SM, Wijeysundera HC. Cost-effectiveness of novel Oral anticoagulants for stroke prevention in non-Valvular atrial fibrillation. Current cardiology reports. 2015;17(8):61.CrossRef Singh SM, Wijeysundera HC. Cost-effectiveness of novel Oral anticoagulants for stroke prevention in non-Valvular atrial fibrillation. Current cardiology reports. 2015;17(8):61.CrossRef
62.
go back to reference Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J. 2009;157(6):1064–73.CrossRef Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J. 2009;157(6):1064–73.CrossRef
63.
go back to reference Stambler BS, Ngunga LM. Atrial fibrillation in sub-Saharan Africa: epidemiology, unmet needs, and treatment options. International journal of general medicine. 2015;8:231–42.CrossRef Stambler BS, Ngunga LM. Atrial fibrillation in sub-Saharan Africa: epidemiology, unmet needs, and treatment options. International journal of general medicine. 2015;8:231–42.CrossRef
64.
go back to reference Tadros R, Shakib S. Warfarin--indications, risks and drug interactions. Aust Fam Physician. 2010;39(7):476–9.PubMed Tadros R, Shakib S. Warfarin--indications, risks and drug interactions. Aust Fam Physician. 2010;39(7):476–9.PubMed
65.
go back to reference Tarus NK, Pau AK, Sereti I, Kirui FK, Sawe FK, Agan BK, et al. Challenges in management of warfarin anti-coagulation in advanced HIV/aids patients with venous thrombotic events--a CASE series from a research clinic in rural KERICHO, Kenya. East Afr Med J. 2013;90(7):207–13.PubMed Tarus NK, Pau AK, Sereti I, Kirui FK, Sawe FK, Agan BK, et al. Challenges in management of warfarin anti-coagulation in advanced HIV/aids patients with venous thrombotic events--a CASE series from a research clinic in rural KERICHO, Kenya. East Afr Med J. 2013;90(7):207–13.PubMed
66.
go back to reference Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thromb J. 2014;12:20.CrossRef Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thromb J. 2014;12:20.CrossRef
67.
go back to reference Teles JS, Fukuda EY, Feder D. Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo). 2012;10(1):110–5.CrossRef Teles JS, Fukuda EY, Feder D. Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo). 2012;10(1):110–5.CrossRef
68.
go back to reference Verhovsek M, Motlagh B, Crowther MA, Kennedy C, Dolovich L, Campbell G, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr. 2008;8:13.CrossRef Verhovsek M, Motlagh B, Crowther MA, Kennedy C, Dolovich L, Campbell G, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr. 2008;8:13.CrossRef
69.
go back to reference Wagenaar BH, Gimbel S, Hoek R, Pfeiffer J, Michel C, Manuel JL, et al. Stock-outs of essential health products in Mozambique - longitudinal analyses from 2011 to 2013. Tropical medicine & international health : TM & IH. 2014;19(7):791–801.CrossRef Wagenaar BH, Gimbel S, Hoek R, Pfeiffer J, Michel C, Manuel JL, et al. Stock-outs of essential health products in Mozambique - longitudinal analyses from 2011 to 2013. Tropical medicine & international health : TM & IH. 2014;19(7):791–801.CrossRef
70.
go back to reference Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy. 2004;24(12):1668–74.CrossRef Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy. 2004;24(12):1668–74.CrossRef
71.
go back to reference Wu B, Kun L, Liu X, He B. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovasc Drugs Ther. 2014;28(1):87–98.CrossRef Wu B, Kun L, Liu X, He B. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting. Cardiovasc Drugs Ther. 2014;28(1):87–98.CrossRef
Metadata
Title
Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings
Authors
Zipporah Kamuren
Gabriel Kigen
Alfred Keter
Alice Maritim
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2018
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-018-3537-4

Other articles of this Issue 1/2018

BMC Health Services Research 1/2018 Go to the issue